1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72:7–33.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008; 100:1368–79.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002; 20:2284–92.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant. 1999; 3 Suppl 1:72–7.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019; 322:746–55.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, et al. Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017; 10:108.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Sung KW, Lim DH, Son MH, Lee SH, Yoo KH, Koo HH, et al. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma. Neuro Oncol. 2013; 15:352–9.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Sung KW, Lim DH, Yi ES, Choi YB, Lee JW, Yoo KH, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation for atypical teratoid/rhabdoid tumor. Cancer Res Treat. 2016; 48:1408–19.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Sung KW, Son MH, Lee SH, Yoo KH, Koo HH, Kim JY, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study. Bone Marrow Transplant. 2013; 48:68–73.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Ma Y, Lim DH, Cho H, Lee JW, Sung KW, Yoo KH, et al. Tandem high-dose chemotherapy without craniospinal irradiation in treatment of non-metastatic malignant brain tumors in very young children. J Korean Med Sci. 2020; 35:e405.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Ju HY, Moon EK, Lim J, Park BK, Shin HY, Won YJ, et al. Second malignant neoplasms after childhood cancer: A nationwide population-based study in Korea. PLoS One. 2018; 13:e0207243.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Hammal DM, Bell CL, Craft AW, Parker L. Second primary tumors in children and young adults in the North of England (1968-99). Pediatr Blood Cancer. 2005; 45:155–61.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007; 13:559–65.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Laska E, Meisner M, Wanderling J. A maximally selected test of symmetry about zero. Stat Med. 2012; 31:3178–91.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001; 93:618–29.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010; 102:1083–95.
17. Ishida Y, Qiu D, Maeda M, Fujimoto J, Kigasawa H, Kobayashi R, et al. Secondary cancers after a childhood cancer diagnosis: a nationwide hospital-based retrospective cohort study in Japan. Int J Clin Oncol. 2016; 21:506–16.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003; 21:1352–8.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Danner-Koptik KE, Majhail NS, Brazauskas R, Wang Z, Buchbinder D, Cahn JY, et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013; 48:363–8.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, et al. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017; 72:177–85.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Forrest DL, Nevill TJ, Naiman SC, Le A, Brockington DA, Barnett MJ, et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant. 2003; 32:915–23.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Vaxman I, Ram R, Gafter-Gvili A, Vidal L, Yeshurun M, Lahav M, et al. Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis. Bone Marrow Transplant. 2015; 50:706–14.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7:813–20.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Goldsby R, Burke C, Nagarajan R, Zhou T, Chen Z, Marina N, et al. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children’s Oncology Group cohort. Cancer. 2008; 113:2597–604.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Kaatsch P, Reinisch I, Spix C, Berthold F, Janka-Schaub G, Mergenthaler A, et al. Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany. Cancer Causes Control. 2009; 20:965–80.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Kuttesch JF Jr, Wexler LH, Marcus RB, Fairclough D, Weaver-McClure L, White M, et al. Second malignancies after Ewing’s sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996; 14:2818–25.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, et al. Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008; 72:24–33.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Lee JW, Lim DH, Sung KW, Cho HW, Ju HY, Yoo KH, et al. Induction chemotherapy reduces radiation therapy dose and volume in the treatment of intracranial germinoma: results of the SMC-G13 trial. Int J Radiat Oncol Biol Phys. 2020; 108:649–56.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Lim DH, Yoo KH, Lee NH, Lee SH, Sung KW, Koo HH, et al. Intensive chemotherapy followed by reduced-dose radiotherapy for biopsy-proven CNS germinoma with elevated beta-human chorionic gonadotropin. J Neurooncol. 2014; 117:279–85.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998; 90:606–11.
![crossref](/image/icon/bnr_ref_cross.gif)
31. Waespe N, Belle FN, Redmond S, Schindera C, Spycher BD, Rossler J, et al. Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer - A national cohort study. Eur J Cancer. 2021; 145:71–80.
![crossref](/image/icon/bnr_ref_cross.gif)